Sanofi poaches exec from Novartis

Sanofi has selected Paul Hudson, Novartis’ pharma chief, to serve as its new CEO, according to Bloomberg.

Advertisement

Mr. Hudson will replace Oliver Brandicourt, who will retire in September at the age of 63. Mr. Brandicourt has served as CEO of the drugmaker since 2015.

Mr. Hudson has led Novartis’ pharma unit since 2016 and is credited with launching key medicines for the drugmaker. Before coming to Novartis, Mr. Hudson served as the U.S. pharma chief for AstraZeneca.

Marie-France Tschudin will become the new leader of the Novartis pharmaceuticals business unit.

More articles on pharmacy:
Viewpoint: The $2.1M drug price record won’t last long
Purdue Pharma hit with 4 more opioid lawsuits: 4 things to know
EpiPen shortage will drag on: 4 things to know

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Advertisement

Next Up in Pharmacy

  • A series of recent FDA safety actions, drug recalls, label updates and court rulings across pharmacy carry operational implications for…

Advertisement

Comments are closed.